Millie
your market intelligence analyst
Search Results
260 results
Your search is now limited to «AstraZeneca» expert search.
FiercePharmaManufacturing 09/18/2019 09:23
AstraZeneca, eyeing China growth, snags local Linzess rights from partner Ironwood.
More from FiercePharmaManufacturing:
pharmaphorum 09/18/2019 07:35
Leon Wang, president of AstraZeneca China, said: “Linzess is an important new treatment for this type of IBS in China, where there is a specific high unmet medical need.
More from pharmaphorum:
AstraZeneca's Farxiga gets FDA fast track status in heart failure.
More from Pharmaceutical Business Review:
Pharmafile 09/18/2019 04:45
New agreement gives AstraZeneca full responsibility for Linzess in China.
More from Pharmafile:
Business Wire 09/18/2019 02:00
AstraZeneca has substantial experience and capabilities in developing and commercializing medicines in China.
More from Business Wire:
PR Newswire 09/17/2019 13:05
EXTON, Pa., Sept. 17, 2019 /PRNewswire/ -- After two Complete Response Letters resulting in lengthy approval delays, AstraZeneca was finally able to introduce Lokelma, its novel treatment for hyperkalemia, to the US market earlier this year. Lokelma was acquired from ZS Pharma in 2015 for...
More from PR Newswire:
PharmaManufacturing 09/16/2019 16:34
The prospects for an AstraZeneca diabetes drug receiving a major new indication are looking even brighter.
More from PharmaManufacturing:
PMLiVE 09/16/2019 05:44
AstraZeneca’s Farxiga (dapagliflozin) has scored fast track designation (FTD) from the FDA in the US, continuing its upward trajectory in heart failure.
More from PMLiVE:
ETHealthWorld (India) 09/16/2019 03:00
The grant comes after AstraZeneca made strides last month towards its goal of adding heart failure to the conditions that can be treated by Farxiga, putting it ahead of a rival treatment from Eli Lilly.
More from ETHealthWorld (India):
Channel NewsAsia (Singapore) 09/16/2019 02:55
The grant comes after AstraZeneca made strides last month toward its goal of adding heart failure to the conditions that can be treated by Farxiga, putting it ahead of a rival treatment from Eli Lilly.
More from Channel NewsAsia (Singapore):
Seeking Alpha 09/13/2019 15:02
Considering that a lower amount of lines of therapy allowed AstraZeneca's treatment arm to improve clinical outcomes, compared to standard of care, I believe that Imfinzi has a good shot at penetrating this specific lung cancer space.
More from Seeking Alpha:
The partnership between the British Embassy and AstraZeneca is designed to encourage young Egyptian graduates in the faculties of Pharmacy and Medicine to develop innovative digital solutions that will better serve Egyptians in several medical fields, including diabetes and oncology.
More from Middle East North Africa Financial Network (MENAFN):
Korean Biomedical Review 09/11/2019 01:22
Jose Baselga, executive vice president for Oncology Research and Development at AstraZeneca, said, “We are encouraged to see more than a third of small-cell lung cancer patients treated with Imfinzi plus chemotherapy alive at the 18-month landmark, which is remarkable given the aggressive nature of ...
More from Korean Biomedical Review:
MedCity News 09/10/2019 13:29
In August, AstraZeneca said that results of the Phase III NEPTUNE study – combining Imfinzi with tremelimumab, the company’s investigational CTLA-4 inhibitor in first-line metastatic NSCLC – failed to show an improvement in overall survival compared with platinum ...
More from MedCity News:
Reuters.com 09/09/2019 11:49
AstraZeneca's cancer treatment Imfinzi has been shown to prolong survival in a particularly aggressive type of lung cancer by close to three months, as the British drugmaker holds its ground in a crowded field against rival immunotherapy drugs.
More from Reuters.com:
ENDPOINTS 09/09/2019 08:03
The data on AstraZeneca’s Phase III Imfinzi trial is out, and it bodes well for the UK outfit’s bid to get their signature immunotherapy approved for frontline small-cell lung cancer (SCLC.
More from ENDPOINTS:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications